Please wait while the formulary information is being retrieved.
Drug overview for GAVILAX (polyethylene glycol 3350):
Generic name: POLYETHYLENE GLYCOL 3350 (paw-lee-ETH-ih-leen GLY-coll)
Drug class: Hypertonic Laxatives
Therapeutic class: Gastrointestinal Therapy Agents
Glycerin (glycerol), polyethylene glycol (PEG), and sorbitol are hyperosmotic laxatives.
No enhanced Uses information available for this drug.
Generic name: POLYETHYLENE GLYCOL 3350 (paw-lee-ETH-ih-leen GLY-coll)
Drug class: Hypertonic Laxatives
Therapeutic class: Gastrointestinal Therapy Agents
Glycerin (glycerol), polyethylene glycol (PEG), and sorbitol are hyperosmotic laxatives.
No enhanced Uses information available for this drug.
DRUG IMAGES
GAVILAX POWDER
The following indications for GAVILAX (polyethylene glycol 3350) have been approved by the FDA:
Indications:
Constipation
Professional Synonyms:
None.
Indications:
Constipation
Professional Synonyms:
None.
The following dosing information is available for GAVILAX (polyethylene glycol 3350):
Prior to bowel cleansing, a copy of the patient information (containing careful instructions on the proper methods of reconstitution and administration of the laxatives) provided by the manufacturer should be given to the patient.
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for GAVILAX (polyethylene glycol 3350):
There are 0 contraindications.
There are 2 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Trofinetide/Laxatives SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Trofinetide commonly causes diarrhea of mild to moderate severity. Laxatives may increase the incidence or severity of diarrhea.(1) CLINICAL EFFECTS: Concurrent use of laxatives with trofinetide may increase the risk of severe diarrhea.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Patients should stop laxatives before starting trofinetide. If diarrhea occurs, consider anti-diarrheal treatment and monitor hydration status. If severe diarrhea or dehydration occurs, interrupt, reduce dose, or discontinue trofinetide.(1) DISCUSSION: In clinical trials, 85% of patients on trofinetide developed diarrhea. Concurrent use of laxatives may increase this risk.(1) |
DAYBUE |
| Tenapanor/Laxatives; Stool Softeners SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Tenapanor commonly causes diarrhea of mild to moderate severity. Laxatives and stool softeners may increase the incidence or severity of diarrhea.(1) CLINICAL EFFECTS: Concurrent use of laxatives or stool softeners with tenapanor may increase the risk of severe diarrhea.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of tenapanor states that patients should be instructed to avoid stool softeners and laxatives with tenapanor. If severe diarrhea occurs, tenapanor should be discontinued.(1) DISCUSSION: In clinical trials, 43-53% of CKD patients on dialysis treated with tenapanor developed diarrhea. Diarrhea usually occurred soon after treatment initiation and was severe in 5% of patients.(1) |
XPHOZAH |
There are 0 moderate interactions.
The following contraindication information is available for GAVILAX (polyethylene glycol 3350):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 5 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Gastrointestinal obstruction |
| Gastrointestinal perforation |
| Ileus |
| Toxic colitis |
| Toxic megacolon |
There are 5 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Gastric retention |
| Hypokalemia |
| Hyponatremia |
| Predisposition to aspiration |
| Seizure disorder |
There are 4 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Hypocalcemia |
| Kidney disease with reduction in glomerular filtration rate (GFr) |
| Severe ulcerative colitis |
| Severe vomiting |
The following adverse reaction information is available for GAVILAX (polyethylene glycol 3350):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 37 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Acidosis Hypercalcemia Hyperkalemia Hypernatremia Hyperuricemia Hypocalcemia Hypokalemia Hypomagnesemia Hyponatremia Hypophosphatemia Urticaria |
| Rare/Very Rare |
|---|
|
Abnormal hepatic function tests Acute pulmonary edema Anaphylaxis Angioedema Asystole Atrial fibrillation Cardiac arrhythmia Dyspnea Esophageal perforation Facial edema Gastritis Hypertension Ischemic colitis Kidney disease with reduction in glomerular filtration rate (GFr) Lip swelling Peripheral edema Pulmonary edema Seizure disorder Skin rash Syncope Tachycardia Throat constriction Tongue swelling Tremor Ulceration of colon Upper GI bleed |
There are 22 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Abdominal distension Abdominal pain with cramps Acute abdominal pain Dehydration Malaise Nausea Polydipsia Rectal irritation Sleep disorder Upper abdominal pain Vomiting |
Dizziness Dyspepsia Headache disorder Rhinorrhea |
| Rare/Very Rare |
|---|
|
Chest tightness Chills Fever Fluid volume disorder Palpitations Pruritus of skin Skin inflammation |
The following precautions are available for GAVILAX (polyethylene glycol 3350):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for GAVILAX (polyethylene glycol 3350):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for GAVILAX (polyethylene glycol 3350)'s list of indications:
| Constipation | |
| K59.0 | Constipation |
| K59.00 | Constipation, unspecified |
| K59.01 | Slow transit constipation |
| K59.03 | Drug induced constipation |
| K59.04 | Chronic idiopathic constipation |
| K59.09 | Other constipation |
Formulary Reference Tool